Mercaptopurine

Preferred Label : Mercaptopurine;

MeSH definition : An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.;

MeSH synonym : 6-thiohypoxanthine; 6 thiopurine; 1,7-dihydro-6h-purine-6-thione; 6 thiohypoxanthine; 6-thiopurine; 6 mercaptopurine monohydrate; 6 mercaptopurine; 6-Mercaptopurine Monohydrate; 6-Mercaptopurine; 6H-Purine-6-thione, 1,7-dihydro-;

CISMeF synonym : 6112-76-1 (6-Mercaptopurine monohydrate); wellcome brand of 6-Mercaptopurine; wellcome brand of 6 mercaptopurine; GlaxoSmithKline brand of 6-Mercaptopurine; GlaxoSmithKline brand of 6 mercaptopurine; glaxo wellcome brand of 6-Mercaptopurine; glaxo wellcome brand of 6 mercaptopurine; puri nethol;

DeCS synonym : Mecaptopurine Anhydrous;

MeSH hyponym : 6-Mercaptopurine monohydrate; purimethol; BW 57-323H; mercaptopurina wellcome; purinethol; leupurin; Puri-Nethol; BW 57 323H; BW 57323H;

MeSH CAS label : 6H-Purine-6-thione, 1,7-dihydro-;

MeSH Related Number : 6-Mercaptopurine monohydrate; 50-44-2 (6-Mercaptopurine); 6112-76-1 (monohydrate); PKK6MUZ20G;

Registry Number MeSH : 50-44-2;

Related CAS MeSH : E7WED276I5 (6-Mercaptopurine monohydrate);

Wikipedia link : https://en.wikipedia.org/wiki/Mercaptopurine;

Codes EINECS : 200-037-4;

Is substance : O;

UNII : E7WED276I5;

InChIKey : WFFQYWAAEWLHJC-UHFFFAOYSA-N;

Details

Origin ID

D015122;

UMLS CUI

C0000618;

ATC code(s)
- mercaptopurine [ATC Code]
Allowable qualifiers
- administration and dosage [MeSH Qualifier]
- adverse effects [MeSH Qualifier]
- agonists [MeSH Qualifier]
- analogs and derivatives [MeSH Qualifier]
- analysis [MeSH Qualifier]
- antagonists and inhibitors [MeSH Qualifier]
- blood [MeSH Qualifier]
- cerebrospinal fluid [MeSH Qualifier]
- chemical synthesis [MeSH Qualifier]
- chemistry [MeSH Qualifier]
- classification [MeSH Qualifier]
- contraindications [MeSH Qualifier]
- economics [MeSH Qualifier]
- history [MeSH Qualifier]
- immunology [MeSH Qualifier]
- isolation and purification [MeSH Qualifier]
- metabolism [MeSH Qualifier]
- pharmacokinetics [MeSH Qualifier]
- pharmacology [MeSH Qualifier]
- poisoning [MeSH Qualifier]
- radiation effects [MeSH Qualifier]
- standards [MeSH Qualifier]
- supply and distribution [MeSH Qualifier]
- therapeutic use [MeSH Qualifier]
- toxicity [MeSH Qualifier]
- urine [MeSH Qualifier]
CISMeF manual mappings
- mercaptopurine [Substance BNPC]
Currated CISMeF NLP mapping
- Mercaptopurine [ICD-11 Extension code]
- Mercaptopurine [LOINC component]
- Mercaptopurine [ICHI extension code]
- Mercaptopurine [NCIt concept]
- Mercaptopurine (substance) [SNOMED CT concept]
- mercaptopurine [SNOMED Notion]
Indexing information
- DC(M)VP protocol [MeSH Supplementary Concept]
Pharmacological action(s)
- antimetabolites, antineoplastic [MeSH Descriptor]
- immunosuppressive agents [MeSH Descriptor]
- nucleic acid synthesis inhibitors [MeSH Descriptor]
Record concept(s)
- BW 57-323H [MeSH concept]
- Mecaptopurine Anhydrous [MeSH concept]
- Mercaptopurine [MeSH concept]
- leupurin [MeSH concept]
- mercaptopurina wellcome [MeSH concept]
- purimethol [MeSH concept]
- purinethol [MeSH concept]
Related MeSH Supplementary Concept(s)
- (9H-purin-6-yl)thiomethyl glutamate [MeSH Supplementary Concept]
- 2,8-dimercapto-6-hydroxypurine [MeSH Supplementary Concept]
- 2-piperidino-8-mercaptoadenine [MeSH Supplementary Concept]
- 6-((1-naphthylmethyl)sulfanyl)-9H-purine [MeSH Supplementary Concept]
- 6-(2,4-dinitrophenyl)mercaptopurine [MeSH Supplementary Concept]
- 6-(decyldithio)-1H-purine [MeSH Supplementary Concept]
- 6-(phenyldithio)purine [MeSH Supplementary Concept]
- 6-carboxymethylthiopurine [MeSH Supplementary Concept]
- 6-ethylthiopurine [MeSH Supplementary Concept]
- 6-mercapto-9-(tetrahydro-2-furyl)purine [MeSH Supplementary Concept]
- 6-mercaptopurine 7-N-oxide [MeSH Supplementary Concept]
- 6-methylmercapto-8-hydroxypurine [MeSH Supplementary Concept]
- 6-methylthiopurine [MeSH Supplementary Concept]
- 6-trimethylsilylthio-9-trimethylsilylpurine [MeSH Supplementary Concept]
- 7+3 protocol [MeSH Supplementary Concept]
- 9-(n-butyl)-6-mercaptopurine [MeSH Supplementary Concept]
- 9-ethyl-6-mercaptopurine [MeSH Supplementary Concept]
- A-VBM-FH6 protocol [MeSH Supplementary Concept]
- ACMP protocol [MeSH Supplementary Concept]
- ACOP protocol 2 [MeSH Supplementary Concept]
- AIEOP 8703 protocol [MeSH Supplementary Concept]
- AIEOP acute lymphoblastic leukemia protocol [MeSH Supplementary Concept]
- AIEOP protocol 8202 [MeSH Supplementary Concept]
- ALL-80 protocol [MeSH Supplementary Concept]
- ALL-82 protocol [MeSH Supplementary Concept]
- ALL-85 protocol [MeSH Supplementary Concept]
- ALL-BFM-95 protocol [MeSH Supplementary Concept]
- APO combination [MeSH Supplementary Concept]
- B-0N compound [MeSH Supplementary Concept]
- B-DOMP protocol [MeSH Supplementary Concept]
- BFHM protocol [MeSH Supplementary Concept]
- BFM-86 protocol [MeSH Supplementary Concept]
- BH-AC-AMP protocol [MeSH Supplementary Concept]
- BH-AC-DMP protocol [MeSH Supplementary Concept]
- BHAC-AMP protocol [MeSH Supplementary Concept]
- BHAC-DMPV protocol [MeSH Supplementary Concept]
- BMF phase II protocol [MeSH Supplementary Concept]
- CCG-141 protocol [MeSH Supplementary Concept]
- DCMP protocol [MeSH Supplementary Concept]
- DOAPP protocol [MeSH Supplementary Concept]
- GAP-POMP regimen [MeSH Supplementary Concept]
- HR-1 protocol [MeSH Supplementary Concept]
- M-DOMP protocol [MeSH Supplementary Concept]
- MOPA-6 protocol [MeSH Supplementary Concept]
- POG 8493 protocol [MeSH Supplementary Concept]
- POG 8602 protocol [MeSH Supplementary Concept]
- POG-8498 protocol [MeSH Supplementary Concept]
- POMP protocol [MeSH Supplementary Concept]
- S-(6-purinyl)cysteine [MeSH Supplementary Concept]
- S6-methylthio-2-aminopurne [MeSH Supplementary Concept]
- T-8801 protocol [MeSH Supplementary Concept]
- TOTAL-XII protocol [MeSH Supplementary Concept]
- VEMP protocol 1 [MeSH Supplementary Concept]
- arabinosyl-6-mercaptopurine [MeSH Supplementary Concept]
- azathiopurine [MeSH Supplementary Concept]
- bismuth-6-mercaptopurine [MeSH Supplementary Concept]
- buthiopurine [MeSH Supplementary Concept]
- butocin [MeSH Supplementary Concept]
- carsatrin [MeSH Supplementary Concept]
- cloturin [MeSH Supplementary Concept]
- methyl-6-mercatopurine [MeSH Supplementary Concept]
- non-Hodgkin's lymphoma protocol 8503 [MeSH Supplementary Concept]
- palladium-6-mercaptopurine [MeSH Supplementary Concept]
- protocol 8001 [MeSH Supplementary Concept]
- st jude's regimen [MeSH Supplementary Concept]
- tris(6-mercaptopurine)iron(II) [MeSH Supplementary Concept]
- xylosyl-6-mercaptopurine [MeSH Supplementary Concept]
Semantic type(s)
- Nucleic Acid, Nucleoside, or Nucleotide [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Mercaptopurine [ICD-11 Extension code]
- Mercaptopurine [NCIt concept]
- Mercaptopurine [LOINC component]
- Mercaptopurine (substance) [SNOMED CT concept]
- Product containing mercaptopurine (medicinal product) [SNOMED CT concept]
- mercaptopurine [ATC Code]
- mercaptopurine [Substance BNPC]
- mercaptopurine [SNOMED Notion]
Validated automatic mappings to BTNT
- mercaptopurine [ATC Code]

Keyword's position in hierarchy(ies) :

Main resources

You can consult :

recommendations
documents concerning education
documents for patients